Navigation Links
Poniard Pharmaceuticals Reports Second Quarter 2008 Financial Results and Corporate Update
Date:7/31/2008

- Conference Call Today at 5:00 p.m. Eastern Time -

SOUTH SAN FRANCISCO, Calif., July 31 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today reported on its corporate progress and financial results for the second quarter ended June 30, 2008.

"Our strategy and focus are to develop picoplatin as an oncology platform compound addressing multiple indications, combinations and formulations. Our accomplishments during the second quarter are consistent with this objective," said Jerry McMahon, Ph.D., chairman and CEO of Poniard. "We are on track to commercialize picoplatin for the treatment of small cell lung cancer (SCLC) in 2010. We presented data at the American Society of Clinical Oncology (ASCO) Annual Meeting in June, illustrating the platform potential of picoplatin in multiple solid tumor indications, including metastatic colorectal cancer (CRC), hormone refractory prostate cancer (HRPC) and ovarian cancer. Data from these trials could support future trials and may be of significant interest to potential partners. We are building a comprehensive strategy to direct our clinical development plan for further development of picoplatin in a wide range of tumor types."

Second Quarter and Recent Highlights

Picoplatin Clinical Development Program

-- Small Cell Lung Cancer: Presented final data in April from our Phase 2 trial of picoplatin in SCLC at the International Association for the Study of Lung Cancer and the European Society for Medical Oncology's 1st European Lung Cancer Conference. Final efficacy results confirmed previously announced interim results showing median overall survival in the picoplatin Phase 2 trial w
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. Poniard Pharmaceuticals Announces Upcoming Conference Participation
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
7. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
8. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
9. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
10. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
11. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... through fast-moving waters may be at risk, suggests new ... salmon encounter turbulent, fast-moving water such as rapids ... upstream using a behaviour known as "burst swimming" that ... sockeye passed through extremely fast-moving water, we started to ... spawning grounds," said Nicholas Burnett, a research biologist at ...
(Date:8/20/2014)... common cause of endophthalmitis, a potentially blinding condition that ... injections, are the well-known staphylococci ("staph") and ... study published in the August issue of Ophthalmology ... of cases at New York Eye and Ear Infirmary ... found that gram-positive bacteria, which include staph and strep ...
(Date:8/20/2014)... By Steven Reinberg ... -- A rare birth disorder that dismantles a baby,s immune ... study of more than 3 million infants says. This ... for the life-threatening but treatable condition known as severe combined ... "People were made aware of this condition by the boy ...
(Date:8/20/2014)... 20, 2014 Get the report here: ... mergermarket presents “Deal Drivers 2014 Half Year Report for ... M&A activity in both North and South America, with ... About Merrill DataSite     , Merrill DataSite is a ... the due diligence process by providing a highly efficient ...
(Date:8/20/2014)... owners looking for ways to make smart changes – and ... check out the latest blog post from Per Wickstrom on ... blog post, which is entitled “Small Changes that Can Have ... , Opportunities for making minor improvements abound, but many ... alert and focused. , Changes shouldn’t be based ...
Breaking Medicine News(10 mins):Health News:Salmon forced to 'sprint' less likely to survive migration 2Health News:Researchers pinpoint most common causes of dangerous eye infection post surgery and trauma 2Health News:Researchers pinpoint most common causes of dangerous eye infection post surgery and trauma 3Health News:'Bubble Boy' Disease May Be More Common Than Thought 2Health News:'Bubble Boy' Disease May Be More Common Than Thought 3Health News:Register to Download Merrill DataSite's Report: Deal Drivers 2014 Half Year Report for the Americas 2Health News:Per Wickstrom’s Latest Blog Post Focuses on Small Changes that Can Have a Big Impact on Business 2
... - including Parkinson's, Alzheimer's, Diffuse Lewy body disease, ... synucleinopathies. Most commonly they become symptomatic due to ... the case of Parkinson's it is dopamine. When ... become impaired, which occurs with oxidation, the eventual ...
... men over the age of 40 years and is the ... goes undetected till it is advanced and beyond cure. However ... and now men over the age of 40 years can ... the most promising "tumour markers" in medicine was developed over ...
... Paul Greengard and Eric Kandel won the Nobel ... transduction in the nervous system." The three Nobel ... prize for their pioneering discoveries "concerning one type ... as slow synaptic transmission," according to the award ...
... that more than two-thirds of births in Russia are marred ... clinic is suffering health problems. , ,The number of ... 30 percent last year, said Olga Frolova, head of the ... that the decline is due to the spread of heavy ...
... drug could make millions of people suffering from ... Disease (COPD) or smoker’s lung, is an irreversible progressive ... emphysema and chronic bronchitis. In tests involving 500 people ... decade, the drug appeared to be safer and better ...
... Researchers at the University of Texas Health Science Center at ... dish from single mouse cells - and they think humans ... direction where they could take ,initial tissue from a [human] ... tooth for them.To accomplish this seemingly futuristic feat, researchers need ...
Cached Medicine News:
(Date:8/20/2014)... , Aug. 20, 2014 Research and ... Report of Pralmorelin" report to their offering. ... providing comprehensive data on Pralmorelin globally and regionally ( ... North America , Latin America ... Pralmorelin This report focuses on three primary areas; ...
(Date:8/20/2014)... Mass. , Aug. 20, 2014 /PRNewswire/ ... electrophysiology (EP) mapping and ablation device market ... use ablation to treat atrial fibrillation (AF). ... primary treatment option for AF will spur ... this application, such as advanced loop diagnostic ...
(Date:8/20/2014)... -- Glades Drugs, an independent pharmacy chain based out of ... into a new corporate headquarters in Lake Worth, ... and state of the art lab. With this expansion Glades ... the new facility. The newly acquired office ... chain,s corporate headquarters and closed door pharmacy, and is in ...
Breaking Medicine Technology:Global Market Report of Pralmorelin 2Electrophysiology Mapping and Ablation Device Market in Japan to Reach $1.1 Billion by 2023 2Electrophysiology Mapping and Ablation Device Market in Japan to Reach $1.1 Billion by 2023 3Glades Drugs Moves to New Corporate Headquarters, 100 Open Positions 2
... the best EMR value for many medical ... Charting Plus™ relies heavily on a user-friendly ... improve documentation quality and increase productivity in ... specific to your medical specialty. Each program ...
... The Frontier device is a ... with one atrial and two ... chronic atrial fibrillation (AF) who ... ablation and who have NYHA ...
Intrinsic Dual Chamber ICD With MVP Mode (Managed Ventricular Pacing). MVP promotes intrinsic conduction and is clinically proven to reduce unnecessary right ventricular (RV) pacing to approximately...
Provides the security of suture and ease of automated knot tying for vascular closure of 5-8F....
Medicine Products: